The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death
Abstract
PURPOSE: To identify and analyze postmarketing cases of complex sleep behaviors (CSBs) resulting in serious injuries, including death, associated with eszopiclone, zaleplon, or zolpidem (Z-drugs). METHODS: Retrospective analysis of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 16 December 1992 through 27 February 2018 and medical literature using PubMed and EMBASE. We used random sampling and descriptive statistics. RESULTS: We identified 66 cases that met inclusion and exclusion criteria, four of which were identified in the medical literature. Twenty cases reported death and 46 cases reported serious injuries in association with CSBs occurring after the use of a Z-drug. Fatal cases described events, such as carbon monoxide poisoning, drowning, falls, hypothermia, motor vehicle collisions, and apparent completed suicide. Nonfatal cases resulting in serious injuries described events, such as accidental overdoses, falls, gunshot wounds, hypothermia, third-degree burns, and self-injuries or suicide attempts. Twenty-two cases reported a previous episode of a CSB while taking a Z-drug prior to the event reported in this case series. CONCLUSIONS: The FAERS and medical literature cases support the need for increased awareness of the consequences that may occur because of CSBs associated with the use of Z-drugs. Therefore, to protect public health, regulatory actions were taken, including adding a Boxed Warning, a Contraindication in patients who have experienced a prior episode of a CSB with a Z-drug, and updating the existing Warnings and Precautions. An FDA Drug Safety Communication was also disseminated to alert healthcare professionals and the public of this potential risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While the Z-drug Zolpidem has a relatively high risk of inducing a NREM parasomnia episode [6,96,97], especially in predisposed subjects”
From Diagnosis and Management of NREM Sleep Parasomnias in Children and Adults (2023) · cites this paper as [97]
Citations
Cites
The International Classification of Sleep Disorders
Greenblatt, D. W. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530270020006 · Cited by 1,559
Probability of adverse events that have not yet occurred: a statistical reminder
Eypasch, E., Lefering, R., Kum, C. K., & Troidl, H. (1995) · BMJ · doi:10.1136/bmj.311.7005.619 · Cited by 336
Pressman, M. R. (2007) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2006.06.003 · Cited by 285 · cited 2×
“NREM-related parasomnias, including CSBs, are diagnosed based on clinical history; there are no reliable biomarkers or laboratory findings for confirming diagnosis.(9) Sleepwalking is more common in children, with a childhoodprevalence rate of 5.”
BackgroundLimitations and strengths of spontaneous reports data
Goldman, S. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80007-6 · Cited by 242
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf, M. B., Roth, T. G., Vogel, G. W., & Walsh, J. K. (1994) · PubMed · Cited by 223
Sieghart, W., & Savić, M. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014449 · Cited by 210
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
Precipitating factors of somnambulism: Impact of sleep deprivation and forced arousals
Pilon, M., Montplaisir, J., & Zadra, A. (2008) · Neurology · doi:10.1212/01.wnl.0000304082.49839.86 · Cited by 158
Prevalence of Sleepwalking: A Systematic Review and Meta-Analysis
Stallman, H. M., & Kohler, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164769 · Cited by 146
Medication induced sleepwalking: A systematic review
Stallman, H. M., Kohler, M., & White, J. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.01.005 · Cited by 112 · cited 1×
“Measures that may reduce the likelihood of a CSB while taking a Z-drug include: using the smallest dose of a Z-drug for the shortest duration; avoiding concurrent use of CYP3A4 inhibitors; avoiding concurrent use of other sedatives and alcohol; ensuring any comorbid sleep disorders, such as obstructive sleep apnea, ar…”
Research works printed but not linked: 2
- Southworth MR. Zaleplon Eszopiclone and Zolpidem and Sleep Driving. FDA ODS Postmarketing Safety Review: PID # D060196;2006.
- U.S. Food and Drug Administration. Code of Federal Regulations Title 21 Volume 5 Chapter 1 Section 314.80 Postmarketing reporting of adverse drug experiences. Revised as of April 1 2018.
Cited by
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Sleep disorders in autoimmune encephalitis
Lopetegi, A. M., Graus, F., Dalmau, J. O., & Santamaría, J. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30341-0 · Cited by 118
Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions
Wingelaar-Jagt, Y. Q., Wingelaar, T. T., Riedel, W. J., & Ramaekers, J. G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.712628 · Cited by 138
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
Palagini, L., & Bianchini, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.893015 · Cited by 53
Diagnosis and Management of NREM Sleep Parasomnias in Children and Adults
Mainieri, G., Loddo, G., Provini, F., Nobili, L., Manconi, M., & Castelnovo, A. (2023) · Diagnostics · doi:10.3390/diagnostics13071261 · Cited by 34
Lou, B. X., & Oks, M. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.04.003 · Cited by 37
Dual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease
Ragsdale, S. M., Radovich, J. M., Coiduras, I. I., McCall, W. V., Grant, S. C., Lee, C. S., & Wilber, A. A. (2025) · npj Biological Timing and Sleep · doi:10.1038/s44323-025-00025-5 · Cited by 28
Challenges in diagnosing NREM parasomnias: Implications for future diagnostic classifications
Lopez, R., & Dauvilliers, Y. A. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101888 · Cited by 21
Toyoshima, M., Noguchi, Y., Otsubo, M., Tachi, T., & Teramachi, H. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51658 · Cited by 15
Mansi, E. T., Rentsch, C. T., Bourne, R. S., Guthrie, B., & Lone, N. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70056 · Cited by 7
Mansi, E. T., Rentsch, C. T., Bourne, R. S., Jeffery, A., Guthrie, B., & Lone, N. (2025) · Intensive Care Medicine · doi:10.1007/s00134-024-07762-4 · Cited by 7
Hypnotic Medications as an Adjunct Treatment to Cognitive Behavioral Therapy for Insomnia
Barkopoulos, P., & Cho, H. J. (2023) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.10.004 · Cited by 7
Joung, K.-I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1256245 · Cited by 11
Mansi, E. T., Rentsch, C. T., Bourne, R. S., Guthrie, B., & Lone, N. (2024) · Journal of the Intensive Care Society · doi:10.1177/17511437231223470 · Cited by 8
Ernstsen, L., Zotcheva, E., Sui, X., Engstrøm, M., Martínez‐Velilla, N., Bjerkeset, O. A., Bjorvatn, B., & Havnen, A. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.08.013 · Cited by 5
Karhana, S., Hussain, S., Zehgeer, M. M., & Khan, M. A. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70007 · Cited by 4
Dementia and Sleep Disorders: The Effects of Drug Therapy in a Systematic Review
Chavez-Mendoza, L. F., Vázquez‐Álvarez, A. O., Torres-Mendoza, B. M., Trujillo-Rangel, W. Á., Torres-Sánchez, E. D., Bracho‐Valdés, I., & Delgado-Lara, D. L. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125654 · Cited by 4
Predicting Hypnotic Use among Insomnia Patients with the Theory of Planned Behavior and Craving
Yang, C., Lai, Y.-S., Huang, Y., Huang, Y.-C., & Lee, H. (2022) · Behavioral Sciences · doi:10.3390/bs12070209 · Cited by 4
Krüger, T. H. C., Becker, E.-M., & Kostev, K. (2022) · Healthcare · doi:10.3390/healthcare11010077 · Cited by 4
Nonrapid Eye Movement Parasomnias
Augustine, A. V. (2022) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0000000000000945 · Cited by 4
Anxiolytic-like effects of the dual orexin receptor antagonist daridorexant in rats
Steiner, M. A., Locher, R., Lecourt, H., & Jenck, F. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104056 · Cited by 3
Preiß, M., Rabl, U., Popper, V., Watzal, V., Treiber, M., Ivkic, D., Praschak-Rieder, N., Naderi‐Heiden, A., Fugger, G., Frey, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1204009 · Cited by 3
Nocturnal agitation: From sleep state dissociation to sleep-related dissociative state
Lopez, R., Micoulaud‐Franchi, J., Peter‐Derex, L., & Dauvilliers, Y. A. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.07.003 · Cited by 5
Sobolewski, K. A. (2021) · Side effects of drugs annual · doi:10.1016/bs.seda.2021.09.013 · Cited by 4
Cloughesy, J. N., Linder, J. A., Knight, T. K., Persell, S. D., Sullivan, M. D., Meeker, D., Brown, T., Lee, J. Y., Stewart, E. A., Fox, C. R., et al. (2025) · Trials · doi:10.1186/s13063-025-09385-6 · Cited by 1
Gysling, E. (2020) · pharma-kritik · doi:10.37667/pk.2020.1117
Krause, A., & Seifert, R. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_26
From Foot-Bread to Flip-Flop Circuits: What History Can Teach Us About Sleep and How to Treat It
Green, Y., Green, Y. S., Yau, B. N., & Ross, D. A. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.08.007
Krause, A., & Seifert, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_26
Wingelaar-Jagt, Y. Q. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240926yw
Krause, A., & Seifert, R. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_26
Zopiclone Discontinuation–Associated Transient Sleepwalking Behavior: A Case Report
Xu, W., Wang, X., Xu, J., Yang, Z., & Gao, J. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002045
The Association of Zolpidem and Suicidality in Psychiatric Outpatients With Insomnia
Jung, J. Y., Yeo, H., Kim, H., Kim, Y., Yoon, S. J., Lyoo, I. K., & Kim, S. J. (2025) · Psychiatry Investigation · doi:10.30773/pi.2024.0397 · Cited by 2
NEUROPSYCHIATRIC ADVERSE EFFECTS OF NEWER SEDATIVE HYPNOTICS: A SYSTEMATIC REVIEW
DAS, P., DAS, D., & Tigga, R. (2025) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2025v17i9.55462
Vornorexant: a shorter-acting addition to the dual orexin receptor antagonist class
McCall, C. (2025) · SLEEP · doi:10.1093/sleep/zsaf374
Kteish, R., Ednick, M., & Kier, C. (2026) · Pediatrics in Review · doi:10.1542/pir.2024-006687
Z-Drug Use and All-Cause Mortality: A Meta-Analysis of Observational Cohort Studies
Park, J.-Y., Park, H. J., Ko, H., Kim, A., Song, J.-E., & Hong, H.-E. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s556191
Krause, A., & Seifert, R. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_26
Shadin, M., Bhuia, M. S., Alfaifi, M., Altemani, A. H., Altemani, F. H., Alsenani, F., Chowdhury, R., & Islam, M. T. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05188-x
Z-Drugs in the Environment: A Review
Topolewska, A., Zahorska, A., Łakocka, A., & Kumirska, J. (2026) · Molecules · doi:10.3390/molecules31060974
Thota, P., Sunkaraboina, S., Mallesham, P., Shivakumar, K., Ethiraj, K. S., Yennam, S., & Behera, M. (2026) · Journal of Chemical Sciences · doi:10.1007/s12039-026-02484-0
May, J. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00183-4
Piech, B., Dubaj, M., Judzińska, A., Trojanowska, E., Osipowska, J., Ignarska, J., Sobczyńska, K., Terbosh, M., Kwolek, M., & `Mzabi, S. K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5601
Akasaka, F., Akasaka, K., Okada, K., Yamaguchi, N., Haruki, Y., & Sadahiro, S. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70162
Xin, W., Li, X., Qu, W., Nie, W., Zhao, Y., Wang, H., Yi, H., & Tan, S. (2026) · doi:10.2196/preprints.110943
Metadata
- Authors
- Harbourt, K., Nevo, O. N., Zhang, R., Chan, V., & Croteau, D.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Harbourt, Kelly
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2020-04-22
- Volume
- 29
- Issue
- 6
- Pages
- 684-691
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W3019649063
- Cited by
- 46
- References
- 18
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 2
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacoepidemiology and Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- eszopiclone, zaleplon, zolpidem, Z-drugs, sleep-related injury, carbon monoxide poisoning, drowning, falls, accidental overdose, suicide attempts, adverse drug reactions, drug safety communication, black box warning, FDA Adverse Event Reporting System
- MeSH terms
- Sleep Aids, Pharmaceutical, Eszopiclone, Zolpidem, Acetamides, Adult, Aged, Drug Labeling, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Pyrimidines, Retrospective Studies, Risk Factors, Sleep, Somnambulism, Time Factors, Wounds and Injuries, Treatment Outcome, Adverse Drug Reaction Reporting Systems, Risk Assessment, Parasomnias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.